Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CLSA Premium Ltd. ( (HK:6877) ) has issued an update.
Top Eminent Healthcare Group Limited has announced that independent non-executive director (INED) and lead INED Mr. Zhou Zuyu will resign from the board and all related committee roles with effect from 31 December 2025 due to other business commitments. He leaves without any dispute with the board, and the company has expressed appreciation for his service. The group will appoint veteran financial markets and regulatory executive Mr. Zhou Jiannan as INED, lead INED and chairman of the remuneration committee, as well as a member of the audit, corporate governance and nomination committees, effective 1 January 2026, with annual director’s fees of HK$240,000. With more than three decades of experience across Chinese securities regulation, stock exchanges and asset management, his appointment strengthens the company’s governance and board oversight as it continues to develop its healthcare business.
The most recent analyst rating on (HK:6877) stock is a Hold with a HK$0.15 price target. To see the full list of analyst forecasts on CLSA Premium Ltd. stock, see the HK:6877 Stock Forecast page.
More about CLSA Premium Ltd.
Top Eminent Healthcare Group Limited is a Cayman Islands-incorporated company listed in Hong Kong that operates a healthcare business through its group of subsidiaries. The company focuses on providing medical and health-related services, positioning itself within the broader healthcare sector in the Greater China region.
Average Trading Volume: 675,803
Technical Sentiment Signal: Sell
Current Market Cap: HK$300.9M
See more data about 6877 stock on TipRanks’ Stock Analysis page.